Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
相关临床试验
47
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
2.1%
已完成
42
89.4%
终止
1
2.1%
撤回
3
6.4%
暂无批准数据
- Sanofi and USA Pickleball have launched 'Serve Up Protection,' a campaign to educate older adults about COVID-19 prevention and the FDA-approved NUVAXOVID vaccine. - NUVAXOVID is a protein-based, non-mRNA vaccine that entered the market more than a year after Pfizer's and Moderna's mRNA vaccines, leaving it with a small share of doses administered. - Concern about side effects was the top reason US adults 50 and older skipped COVID-19 vaccination, cited by 26% in a January University of Michigan poll. - Sanofi is positioning NUVAXOVID's generally milder short-term side-effect profile, supported by two pivotal phase 3 studies, as an answer to older adults' vaccination hesitation.
- With the CDC largely silent this fall, the American Medical Association and the University of Minnesota's Vaccine Integrity Project published independent reviews in JAMA to guide flu, Covid-19, and RSV immunization. - New recommendations from the AAP, AAFP, ACOG, and IDSA advise RSV immunization for high-risk adults 50+, everyone over 75, pregnant people, and infants, plus annual flu shots for everyone 6 months and older. - Updated Covid-19 vaccines targeting the XFG Omicron subvariant are recommended for adults, with a second dose six months later for those 65 and older, and insurers have indicated coverage without cost sharing. - The first mRNA flu vaccine is newly available for adults 50 and older, while ACOG extended the maternal RSV vaccine window through March 1 due to a later, more severe RSV season.
- Intismeran Autogene, an individualized neoantigen therapy paired with Merck's Keytruda, hit its primary endpoint in the Phase 3 INTerpath-001 study for skin cancer. - The breakthrough sent Moderna shares soaring more than 100% and Merck up over 12%, lifting rival vaccine makers BioNTech and Novavax. - The SPDR S&P Biotech ETF (XBI) surged more than 5% to its highest level since February 2021, reflecting renewed investor appetite across mRNA and vaccine therapeutics. - Novavax rode the sector-wide optimism despite not being directly involved in the trial, adding momentum to its recent earnings beat and raised 2026 revenue guidance.
- WindRose Health Investors has completed the recapitalization of Verified Clinical Trials (VCT), a global leader in clinical trial subject registry solutions. - Howard Miller, former CEO of Envision Pharma Group, has been appointed as VCT's new Chief Executive Officer to lead the next phase of growth. - Co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will remain actively involved, transitioning to roles focused on long-term strategy and client relationships. - The investment aims to expand VCT's data and analytics capabilities, infrastructure, and geographic reach to better serve pharmaceutical sponsors, CROs, and clinical trial sites.
- The global vaccine sales market is projected to reach US$141.40 billion by 2036, driven by next-generation platforms including mRNA and viral vector technologies. - U.S. tariff policies and cross-border supply chain vulnerabilities are reshaping competitive strategy, with manufacturers localizing production and diversifying suppliers to manage cost pressures. - Competition is increasingly defined by platform capabilities, regulatory credentials, manufacturing scale, and access to government and multilateral procurement contracts. - The report profiles 21 leading vaccine companies including GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca, and Serum Institute of India, with forecasts across 26 national markets.
- The global vaccine adjuvants market was valued at USD 4.00 billion in 2025 and is projected to reach USD 6.19 billion by 2035, growing at a CAGR of 4.47%. - The U.S. market alone is expected to expand from USD 0.62 billion in 2025 to USD 1.61 billion by 2035, reflecting a robust CAGR of 9.05%. - Oncology vaccines represent the fastest-growing application segment, fueled by investments in cancer immunotherapy, personalized vaccines, and neoantigen-based therapies. - Combination adjuvants and intradermal administration are poised for the most rapid growth, while GSK and Novavax continue advancing next-generation adjuvant platforms.
- Novavax reported Q1 revenues of $139.5 million, beating analyst estimates by 96.3% despite a 79.1% year-on-year decline, and announced a new Matrix-M license with Pfizer for up to two vaccine candidates. - Moderna posted $389 million in Q1 revenue, up 260% year-on-year and exceeding expectations by 55.8%, marking the fastest revenue growth among its therapeutic peers. - The 11 tracked therapeutics stocks collectively beat consensus revenue estimates by 15.6%, with share prices rising an average of 3.3% since reporting. - Eli Lilly delivered the standout pharmaceutical performance with $19.8 billion in revenue, up 55.5% year-on-year, surpassing analyst expectations by 13.7%.
- A newly posted ACIP charter dated May 14 substantially refocuses the committee's responsibilities, downplaying vaccine recommendations and emphasizing alternatives to vaccines for disease prevention. - The charter broadens member qualification criteria, replacing specific vaccine expertise requirements with a "balanced range" of scientific, clinical, and public health expertise. - Public health experts and legal observers interpret the changes as an attempt by HHS Secretary Robert F. Kennedy Jr. to circumvent a federal court ruling that suspended ACIP after finding most new members lacked required qualifications. - The ongoing ACIP suspension has created unprecedented ambiguity around the fall 2025 influenza and COVID-19 vaccination campaigns, though experts remain tentatively optimistic that flu shots will still reach Americans.
- The FDA's Vaccines and Related Biological Products Advisory Committee voted to update COVID-19 vaccines to target the XFG variant for the 2026-2027 immunization season. - XFG currently accounts for more than half of U.S. COVID-19 cases and has been the dominant circulating variant globally for over six months. - All four FDA-approved vaccine manufacturers indicated readiness to produce updated formulations, with Moderna prepared to supply by mid-August and Sanofi already manufacturing XFG-targeting vaccines. - The decision comes amid concerns about deteriorating surveillance data quality due to reduced sequencing volumes and cuts to public health funding.
- Novavax reported first-quarter revenue of $139.5 million, significantly surpassing Wall Street estimates of $78.3 million, driven by upfront and milestone payments from vaccine licensing deals. - The company's licensing strategy with partners including Sanofi ($1.2 billion deal) and Pfizer ($30 million Q1 payment) has partially insulated it from declining COVID-19 vaccine demand and policy uncertainty. - Novavax is targeting profitability by 2028 through its COVID-flu combination vaccine rollout and expanding Matrix-M adjuvant partnerships across infectious diseases and oncology applications.
